MEBO Private Facebook Group
to join : contact
maria.delatorre@meboresearch.org

MEBO TMAU urine test

MEBO Research
TMAU Urine Test
United States only
PROGRAM IS TEMPORARILY SUSPENDED AS OF 2 MAY 2017

Click here for
REQUISITION FORM
Incomplete applications
will NOT be processed

SEE UPDATES HERE

1
test
$150 plus
shipping costs
2
tests
$250 plus
shipping costs

TWO PAYMENT PLAN OPTION
Send email to maria.delatorre@meboresearch.org to arrange, AFTER filling out Requisition Form, please.

Test analysis performed in batches of 20 or more

DATE: 2 MAY 2017
Currently on : PROGRAM IS TEMPORARILY SUSPENDED

Samples analyzed since June 2012 :
352
Metabolomic Profiling Study
NCT02683876

Start : Aug 2016
Stage 1 : 27 Canadian volunteers to test
Latest click here (26 oct) :
17 samples returned


Note : Stage 1 is Canada only.
Return cut-off date : passed
Analysis can take 6/8 weeks
Analysis start in/before Nov
MEBO Research is a
EURORDIS and
NORD Member Organization
See RareConnect

MEBO meetup map


Full details : https://goo.gl/TMw8xu
want listed ? contact map@meboresearch.org
BannerFans.com
RESEARCH DETAILS

DONATIONS THRU 31-NOV-2016:
£ 943.03/GBP
$ 568.00/USD

TOTAL at today's ROE
£0.80/GBP = $1.00/USD

£1,398.07 = $1,745.14

MEBO UK PAYPAL FOR TRINZYME

********
MEBO US PAYPAL FOR TRINZYME

Your currency will be automatically converted to USD or GBP by PayPal.

Option: pay with your credit card instead of PayPal account by clicking on either Donate button above.

Popular Posts (last 30 days)

Upcoming get-togethers


Let us know if you want a meetup listed

Subscribe to Blog

Enter your email address:

Delivered by FeedBurner

You will be sent a verification email

Subscribe in a reader

Blog Archive

Monday, June 12, 2017

The People behind the P&G TMA reducing supplement

Readers have been aware since 2015 that a trimethylamine reducing therapy has been on the cards. Here is some background (and guesswork) to the 'therapy' (speculated to be a supplement).

The 2 organisations involved  :
Cleveland Clinic (Innovations)
Procter & Gamble

Cleveland Clinic :
Has a long history of being a pioneer in heart diesease research and treatment.

Dr Stanley Hazen (lab) :
Dr Stanley Hazen is one of the world's leading Heart Disease doctor's and researcher.

In 2011 his lab (Hazen et al) put forward a paper saying that Trimethylamine-n-oxide (TMAO) may be a strong causal factor for developing Heart Disease.pubmed ).
One obvious potential therapy was to stop gut microbes altering the likes of choline into TMA. One possible way to do this would be to interfere with the choline-TMA metabolism.
This seems to be what the patented product will do.
The lab has released many TMAO-CVD papers since 2011.
It seems most of the papers are have Dr Tang as lead researcher.
In this case the end product will probably come under the Cleveland Clinic INNOVATIONS dept. Or Cleveland Heartlab.

Procter & Gamble :
P&G is one of the biggest manufacturer and brand for household products, including some nutrition products.

It seems Cleveland ( Innovations ) have teamed up with P&G probably mostly under a licence agreement whereby P&G are the sellers of the product.

P&G Nutrition products :
A guess is that the TMA-inhibiting product will be sold as part of the P&G Nutrition range.
Perhaps as part of the 'Meta' range.
P&G Nutrition online shop
P&G current heart health product

Product patent (current version Dec 2016) : link

Inventor names on the patent :
Garcia-garcia, Jose Carlos (Cincinnati, OH, US)
Hazen, Stanley Leon (Pepper Pike, OH, US)
Wos, John August (Mason, OH, US)

Garcia-garcia, Jose Carlos.
Principal Scientist at Procter & Gamble

Hazen, Stanley Leon

Wos, John August
Principal Scientist at Procter & Gamble

When will we hear the latest news ?
Probably in a press release. Until they are ready, they will keep all info secret.
One idea is to follow Cleveland Innovations on Twitter.
But it will likely be major news when it is available.

Aug 2015 Press Release

get New Posts by EMAIL : Enter your email address :



A EURORDIS and NORD Member Organization

Thursday, June 8, 2017

P&G TMA inhibitor supplement : 1st sign of patent

TRIMETHYLAMINE INHIBITOR THERAPY

The community has been aware since around August 2015 that Procter & Gamble are working on a supplement which will be a trimethylamine inhibitor in the gut.

For the first time, we can see the patent publicly (published on June 1 2017).
Here is the patent via the freepatentsonline website :
PDF version
Via the site (without images) 
P&G Press Release on product (Aug 2015)

The patent is titled :
COMPOUNDS AND METHODS FOR INHIBITING PRODUCTION OF TRIMETHYLAMINE


It looks like it was filed on Dec 1 2016.

The 'skinny' on this is :
It will be over-the-counter (no prescription needed)
It is being created due to a 2011 paper by Dr Hazen et al at Cleveland Clinic which implicated TMA-oxide as a causal factor in heart disease development.
Dr Hazen et al are working on the supplement under licence to Procter & Gamble.

For now we are digesting the information.
More posts will follow on the subject.
Comments and interpretations are welcome.

Probably the product still has a long way to be on sale.    

The invention provides a method of inhibiting the conversion of choline or carnitine to trimethylamine (TMA) and lowering TMAO in an individual comprising administering to the individual a composition comprising a compound set forth in FORMULA (I)

The invention also provides for a method of inhibiting the production of TMA by bacteria comprising administering to the individual a composition comprising a compound set forth in FORMULA (I) wherein the compound is administered in an amount effective to inhibit formation of trimethylamine (TMA) from choline or carnitine in the individual.


get New Posts by EMAIL : Enter your email address :



A EURORDIS and NORD Member Organization

Wednesday, May 17, 2017

New paper : TMA producing bacteria in human gut

This is a new paper on which gut microbes may produce trimethylamine (TMA) :

Paper :
Uncovering the trimethylamine-producing bacteria of the human gut microbiota.
Silke Rath, Benjamin Heidrich, Dietmar H. Pieper and Marius Vital.
Helmhotz Center for Infection Research, Germany.

It's being posted quickly so people can read it. On 1st glance the specific 'types' of microbes could not be found by us.

It's not known if :
This is new information.
This will be all the gut microbes ever to blame.
If this type of research needs a 'consensus' and papers will show differing results. (i.e. do the experts agree).

So for now, everyone can read the paper at least

Background :
Humans don't 'eat' TMA (it's unpleasant) not produce it in their system. It is sourced from foods and drinks that contain 'TMA precursors', which then microbes break down the precursor and one by-product is TMA.
Known precursors are :
Choline
Carnitine
TMAO (in fish, broken down to TMA)

Currently advice for TMAU is a 'low precurosr' diet, but choline is an important nutrient.

Longterm it would be better for science to come up with a therapy to :
Block of interfere with TMA formation
Alter the flora away from TMA producers
Some other therapy that blocks, interferes or neutralizes TMA in the gut
   

get New Posts by EMAIL : Enter your email address :



A EURORDIS and NORD Member Organization